Skip to main content
Erschienen in: Supportive Care in Cancer 7/2013

01.07.2013 | Original Article

Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia

verfasst von: Rowena E. Vleut, Joyce E. A. M. van Poppel, Marcus W. Dercksen, Mijke Peerbooms, Saskia Houterman, Wim P. M. Breed

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In order to evaluate the efficacy of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA), it is essential to precisely quantify the amount of hair mass that is present. We wanted to determine if the hair mass index (HMI), obtained by cross-section trichometry (CST), was a suitable parameter for hair mass measurement, and whether or not marking the measurement site on the scalp was necessary.

Methods

Ten patients receiving chemotherapy were sequentially measured using CST during their treatment. At the same time, they were asked to report severity of hair loss via three subjective parameters: World Health Organization (WHO) grade, visual analog scale (VAS) score, and patients’ need to wear wig or head cover. To investigate the need of marking of the measurement area, differences in HMI between a random 2 × 2-cm site (HMI-C) and four surrounding areas (HMI-S4) on the scalp of eight volunteers and eight chemotherapy patients were calculated and compared.

Results

Using CTS, hair loss due to CIA was quite measurable and ranged from 13 to 82 %. Reported VAS scores and WHO grades showed an increase in patients in time; 50 % of patients reported the need to wear a wig or head cover. The difference between HMI-S4 and the HMI-C values in all subjects of the marking group was homogeneously distributed between −11 and +10 and was not statistically different between the volunteer and the patient groups (p = 0.465).

Conclusions

CST for HMI measurement is a useful mechanical modality for assessing hair loss in CIA patients. It is quantitatively more precise than existing non-mechanical measuring methods. It is recommended when detection of minor changes in hair quantity is required. Marking a fixed sampling area to ensure return to the exact same site is only required when a minor change in pre- and posttreatment HMI values is anticipated and the mid-line locating device is not/cannot be used.
Literatur
1.
Zurück zum Zitat Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WPM (2009) Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 17(2):181–189PubMedCrossRef Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WPM (2009) Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 17(2):181–189PubMedCrossRef
2.
Zurück zum Zitat Breed WPM, van den Hurk CJG, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy-induced hair loss: scalp cooling potentials and limitations. Expert Rev Dermatol 6(1):109–125CrossRef Breed WPM, van den Hurk CJG, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy-induced hair loss: scalp cooling potentials and limitations. Expert Rev Dermatol 6(1):109–125CrossRef
3.
Zurück zum Zitat Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17(4):317–328PubMedCrossRef Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17(4):317–328PubMedCrossRef
4.
Zurück zum Zitat van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WPM (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19(7):701–709PubMed van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WPM (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19(7):701–709PubMed
6.
Zurück zum Zitat Auvinen PK, Mahonen UA, Soininen KM, Paananen PK, Ranta-Koponen PH, Saavalainen IE et al (2010) The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96(2):271–275PubMed Auvinen PK, Mahonen UA, Soininen KM, Paananen PK, Ranta-Koponen PH, Saavalainen IE et al (2010) The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96(2):271–275PubMed
7.
Zurück zum Zitat Grevelman E, Breed WPM (2005) Review: prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352–358PubMedCrossRef Grevelman E, Breed WPM (2005) Review: prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352–358PubMedCrossRef
8.
Zurück zum Zitat van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JWW, Breed WPM (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients—results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504PubMedCrossRef van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JWW, Breed WPM (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients—results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504PubMedCrossRef
9.
Zurück zum Zitat van den Hurk CJG, Breed WPM, Mols F (2012) Chemotherapy induced hair loss. In: Preedy VR (ed) The handbook of hair in health and disease. Wageningen Academic, Wageningen, pp 403–418 van den Hurk CJG, Breed WPM, Mols F (2012) Chemotherapy induced hair loss. In: Preedy VR (ed) The handbook of hair in health and disease. Wageningen Academic, Wageningen, pp 403–418
10.
Zurück zum Zitat van den Hurk CJ, Coebergh J, Breed WPM, van den Poll-Franse L, Nortier J (2009) Shorter post-infusion cooling time of scalp cooling in the prevention of docetaxel-induced hair loss. Eur J Cancer Suppl 7(2):181CrossRef van den Hurk CJ, Coebergh J, Breed WPM, van den Poll-Franse L, Nortier J (2009) Shorter post-infusion cooling time of scalp cooling in the prevention of docetaxel-induced hair loss. Eur J Cancer Suppl 7(2):181CrossRef
11.
Zurück zum Zitat World Health Organisation (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication, Geneva World Health Organisation (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication, Geneva
12.
Zurück zum Zitat Cohen B (2008) The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth. Dermatol Surg 34(7):900–910, discussion 910–901PubMedCrossRef Cohen B (2008) The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth. Dermatol Surg 34(7):900–910, discussion 910–901PubMedCrossRef
13.
Zurück zum Zitat Cohen B (May/June 2008) Hair breakage: an underappreciated cause of hair loss in women. Hair Transplantation Forum International, 100-101 Cohen B (May/June 2008) Hair breakage: an underappreciated cause of hair loss in women. Hair Transplantation Forum International, 100-101
14.
Zurück zum Zitat Cohen B (2010) The cross-section trichometer. In: Unger WP, Shapiro R, Unger M, Unger R (eds) Hair transplantation, 5th edn. Marcel Dekker, New York, pp 340–343 Cohen B (2010) The cross-section trichometer. In: Unger WP, Shapiro R, Unger M, Unger R (eds) Hair transplantation, 5th edn. Marcel Dekker, New York, pp 340–343
16.
Zurück zum Zitat Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM et al (2005) A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68(4–6):333–340PubMedCrossRef Cho EK, Lee WK, Im SA, Lee SN, Park SH, Bang SM et al (2005) A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68(4–6):333–340PubMedCrossRef
Metadaten
Titel
Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia
verfasst von
Rowena E. Vleut
Joyce E. A. M. van Poppel
Marcus W. Dercksen
Mijke Peerbooms
Saskia Houterman
Wim P. M. Breed
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1723-9

Weitere Artikel der Ausgabe 7/2013

Supportive Care in Cancer 7/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.